LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
© LexDana · beta
LexDanaLexDanabeta
New SessionSearchOfficial RankingsInsightsPricing
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets59Federal Circuit877ITC / Section 33788Patent Litigation216Patent Prosecution126Pharma & ANDA62PTAB686Supreme Court61Trademark158USPTO Policy78Unsorted257

Tagged compulsory licensure · clear

Unsorted

Case Research Notes: Patent Licensing

Dilligent Patexia users may have noticed a new type of contest recently appear on our site: “commercial use” or “licensing” searches. In fact, we just closed our first search of this kind (investigating a particular antibacterial…

February 22, 2013·Unsorted·3 min read
Unsorted

The battle over pharmaceutical patents and the Indian drug market

In the late 1990s, Novartis manufactured and patented imatinib (with the brand name Gleevec), a drug that prolongs life in patients with chronic myelogenous leukemia (CML). Since its release, imatinib has offered hope for patients suffering from (CML);…

March 15, 2012·Unsorted·5 min read
LexDana
AskSearchRankingsInsightsPricingProfileContactTermsPrivacy
The LexDana Docket
Monthly — what shipped, who moved, what we published.
© 2026 LexDana, Inc.·Powered by Patexia data